Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to $1.4 million.

  • Cardiff Oncology's Share-based Compensation rose 1045.49% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 2622.62%. This contributed to the annual value of $4.8 million for FY2024, which is 556.66% up from last year.
  • Cardiff Oncology's Share-based Compensation amounted to $1.4 million in Q3 2025, which was up 1045.49% from $1.7 million recorded in Q2 2025.
  • Cardiff Oncology's 5-year Share-based Compensation high stood at $1.7 million for Q2 2025, and its period low was $268000.0 during Q1 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $1.1 million (2023), whereas its average is $1.1 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 32985.07% in 2022, then plummeted by 2542.69% in 2024.
  • Over the past 5 years, Cardiff Oncology's Share-based Compensation (Quarter) stood at $990000.0 in 2021, then grew by 2.22% to $1.0 million in 2022, then decreased by 10.18% to $909000.0 in 2023, then surged by 32.45% to $1.2 million in 2024, then rose by 14.95% to $1.4 million in 2025.
  • Its Share-based Compensation stands at $1.4 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.4 million for Q1 2025.